as03

Small moleculeexperimental

Clinical trial activity

29 trials · 28 clinical orgs · 0 marketing orgs

Phase 1
12
Phase 2
20
Phase 3
3
Phase 4
1

Earliest trial started Aug 20, 2009 (NCT00964951)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • as03
  • as03
  • as03b

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06560151Phase 2Aug 21, 2024Department of Health and Human Services, ICON, Rho, Inc.
NCT05975840Phase 1/Phase 2 (Phase 2)Aug 3, 2023GlaxoSmithKline
NCT05501522Phase 3Nov 30, 2022Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline, International Vaccine Institute, SK Bioscience Co., Ltd.
NCT05561673Phase 1/Phase 2 (Phase 2)Oct 4, 2022GlaxoSmithKline
NCT05289037Phase 1/Phase 2 (Phase 2)Mar 30, 2022National Institute of Allergy and Infectious Diseases (NIAID)
NCT04959344Phase 1/Phase 2 (Phase 2)Jul 5, 2021GlaxoSmithKline, LimmaTech Biologics AG, Nuvisan Pharma Services
NCT04789577Phase 2Mar 16, 2021GlaxoSmithKline
NCT04750343Phase 1/Phase 2 (Phase 2)Feb 3, 2021Coalition for Epidemic Preparedness Innovations, GlaxoSmithKline, Korea University, SK Bioscience Co., Ltd.
NCT04672395Phase 2/Phase 3 (Phase 3)Dec 31, 2020Clover Biopharmaceuticals, Coalition for Epidemic Preparedness Innovations, International Vaccine Institute
NCT04662697Phase 2Dec 11, 2020Medicago
NCT04405908Phase 1Jun 20, 2020Clover Biopharmaceuticals
NCT03738241Phase 2Dec 18, 2018National Institute of Allergy and Infectious Diseases (NIAID)
NCT03589807Phase 2Aug 14, 2018National Institute of Allergy and Infectious Diseases (NIAID)
NCT03497845Phase 2Mar 15, 2018Department of Health and Human Services
NCT03318315Phase 2Feb 20, 2018National Institute of Allergy and Infectious Diseases (NIAID)
NCT03312231Phase 2Feb 14, 2018National Institute of Allergy and Infectious Diseases (NIAID)
NCT03300050Phase 1Oct 10, 2017Duke University, GlaxoSmithKline, Icahn School of Medicine at Mount Sinai, PATH, The EMMES Corporation, University of Cincinnati
NCT03283319Phase 2Sep 20, 2017Central Kentucky Research Assoc, Inc, Department of Health and Human Services, Heartland Research Associates, LLC, Johnson County Clin-Trials, Rho, Inc., Rochester Clinical Research
NCT03014310Phase 1Jan 17, 2017National Institute of Allergy and Infectious Diseases (NIAID)
NCT02957656Phase 1Dec 1, 2016National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester
Showing 20 of 29 trials
Page 1 / 2

Organizations

Research & Development (28)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government131322009
GlaxoSmithKlineFor profit8332012
Coalition for Epidemic Preparedness InnovationsAcademic/Hospital3022020
Department of Health and Human ServicesGovernment3312017
Clover BiopharmaceuticalsFor profit2222020
International Vaccine InstituteAcademic/Hospital2012020
Rho, Inc.For profit2012017
SK Bioscience Co., Ltd.For profit2222021
Central Kentucky Research Assoc, IncFor profit1012017
Duke UniversityAcademic/Hospital1012017
Erasmus University RotterdamAcademic/Hospital1112009
Free University of BrusselsAcademic/Hospital1012009
Heartland Research Associates, LLCFor profit1012017
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012017
ICONFor profit1012024
Johnson County Clin-TrialsFor profit1012017
Korea UniversityAcademic/Hospital1012021
LimmaTech Biologics AGFor profit1112021
MedicagoFor profit1112020
Nuvisan Pharma ServicesFor profit1012021
28 organizations
Page 1 / 2